Emerging and Evolving Biomarkers: Recent Findings, Laboratory Considerations, and Clinical Implications

The extraordinary advancements made over the past several years in the clinical management of cancer have ushered in a new era of optimism for those afflicted with many cancer types. However, these advancements have also created a highly complex environment for healthcare providers and diagnostic laboratory personnel.

This webinar series will efficiently describe emerging and evolving biomarkers that will be structured to provide a consistent framework for each biomarker. Read more about this series in this JMD article.

Each webinar will feature:

15-20 minutes of a scientific overview of recent and relevant research on the biomarker;
15-20 minutes covering the laboratory considerations for the testing approach to each biomarker;
15-20 minutes of discussion on the clinical implications of biomarker use.

The recordings will be posted as (1) A complete presentation with pre- and post-tests plus available continuing education credit and (2) A series of short microlearning modules (~15 minute videos) that can be reviewed based on need and interest in the science, laboratory applications, and/or clinical implications of each marker.

LEARNING OBJECTIVES

Describe the biological principles that underlie the pathogenicity of each biomarker, including the cellular signaling pathways and cellular processes involved.
Discuss the appropriate technical approaches and platforms for molecular diagnostic testing for each biomarker.
Outline the strengths and limitations of described testing approaches.
Apply biomarker information so as to order appropriate testing and interpret biomarker status results within a clinical context.

Supported by an educational grant from AstraZeneca

LIVE WEBINARS

Germline Variants in Cancer

Thursday, January 30, 2025 | 2:30PM - 3:30PM ET

SPEAKER: Diana Mandelker, MD, PhD Memorial Sloan Kettering

MODERATOR: Rena Xian, MD Johns Hopkins University

ONDEMAND WEBINARS

Click on the icons below to access the full webinar(s) webinar , the 15-min microlearning module(s) (MLM), or the practice advance papers paper .

BIOMARKERS	FULL WEBINAR	SCIENCE MLM	LABORATORY MLM	CLINICAL MLM	PAPER
Endometrial Carcinoma
EGFR Exon 20 Insertions
ERBB2 (HER2) in Colorectal Cancer
FLT 3 Mutations and AML
HRD Score
Immunoglobulin and T-cell Receptor Gene Sequencing
KRAS
METex14
Methylation Profiling
MGMT
MSI Testing for Cancer
Mutational Signatures in Cancer
Myeloid Malignancy MRD
NRG1 Fusions
NTRK
Oncogenic RET Fusions
TP53 Mutations in Myeloid Neoplasms

CONTINUING EDUCATION CREDIT INFORMATION

Accreditation Statements
AMA PRA Category 1 Credit(s)™
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.

The ASCP designates this material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™per webinar. Physicians should claim only credit commensurate with the extent of their participation in the activity.

CMLE
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit per webinar. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.

CONTENT COMMITTEE

This webinar series on Emerging and Evolving Biomarkers (EEB) is planned and coordinated by the Emerging and Evolving Biomarkers Content Committee:

Rena Xian, MD